Measuring hepatitis C virus elimination as a public health threat: Beyond global targets.
van Santen DK, Sacks-Davis R, Doyle JS, Scott N, Prins M, Hellard M
Injection drug network characteristics as a predictor of injection behaviour.
Spelman T, Sacks-Davis R, Dietze P, Higgs P, Hellard M
Australia needs to increase testing to achieve hepatitis C elimination.
Scott N, Sacks-Davis R, Wade AJ, Stoove M, Pedrana A, Doyle JS, Thompson AJ, Wilson DP, Hellard ME
Commentary on Barré et al. (2020): Identifying remaining barriers to hepatitis C treatment in the DAA era.
Sacks-Davis R, van Santen DK, Doyle JS
Linkage and retention in HCV care for HIV-infected populations: early data from the DAA era.
Sacks-Davis R, Doyle JS, Rauch A, Beguelin C, Pedrana AE, Matthews GV, Prins M, van der Valk M, Klein MB, Saeed S, Lacombe K, Chkhartishvili N, Altice FL, Hellard ME
Staying hepatitis C negative: A systematic review and meta-analysis of cure and reinfection in people who inject drugs.
Latham NH, Doyle JS, Palmer AY, Vanhommerig JW, Agius P, Goutzamanis S, Li Z, Pedrana A, Gottfredsson M, Bouscaillou J, Luhmann N, Mazhnaya A, Altice FL, Saeed S, Klein M, Falade-Nwulia OO, Aspinall E, Hutchinson S, Hellard ME, Sacks-Davis R